Brazilian strains of Toxoplasma gondii are controlled by azithromycin and modulate cytokine production in human placental explants by Franco, P. S. et al.
RESEARCH Open Access
Brazilian strains of Toxoplasma gondii are
controlled by azithromycin and modulate
cytokine production in human placental
explants
Priscila Silva Franco1, Paula Suellen Guimarães Gois1, Thádia Evelyn de Araújo1, Rafaela José da Silva1,
Bellisa de Freitas Barbosa1, Angelica de Oliveira Gomes2, Francesca Ietta3, Lara Affonso dos Santos1,
Maria Célia dos Santos1, José Roberto Mineo4 and Eloisa Amália Vieira Ferro1*
Abstract
Background: Toxoplasma gondii is a protozoan parasite that causes congenital toxoplasmosis by transplacental
transmission. Parasite strains are genetically diverse and disease severity is related to the genotype. In Uberlândia
city, Brazil, two virulent strains were isolated: TgChBrUD1 and TgChBrUD2. Congenital toxoplasmosis is more
prevalent in South America compared to Europe, and more often associated with severe symptoms, usually as a
result of infection with atypical strains.
Methods: Considering that T. gondii has shown high genetic diversity in Brazil, the effectiveness of traditional
treatment may not be the same, as more virulent strains of atypical genotypes may predominate. Thus, the aim of
this study were to evaluate the Brazilian strain infection rate in human villous explants and the azithromycin efficacy
with regard to the control of these strains compared to traditional therapy. Villi were infected with RH, ME49,
TgChBrUD1 or TgChBrUD2 strains and treated with azithromycin, spiramycin or a combination of pyrimethamine
plus sulfadiazine. The villous viability was analyzed by LDH assay and morphological analysis. Parasite proliferation,
as well as production of cytokines was analyzed by qPCR and ELISA, respectively. Statistical analysis was performed
using the GraphPad Prism 5.0.
Results: The treatments were not toxic and TgChBrUD1 infected villi showed a higher parasite burden compared
with others strains. Treatments significantly reduced the intracellular proliferation of T. gondii, regardless of the
strain. TgChBrUD1-infected villi produced a larger amount of MIF, IL-6 and TGF-β1 compared with other infected
villi. Azithromycin treatment increased MIF production by RH- or TgChBrUD2-infected villi, but in ME49- or
TgChBrUD1-infected villi, the MIF production was not altered by treatment. On the other hand, azithromycin
treatment induced lower IL-6 production by ME49- or TgChBrUD1-infected villi.
Conclusions: Azithromycin treatment was effective against T. gondii Brazilian strains compared with conventional
treatment. Also, the TgChBrUD1 strain replicated more in villi and modulated important cytokines involved in
parasite control, showing that different strains use different strategies to evade the host immune response and
ensure their survival.
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Background
Toxoplasmosis is a disease caused by Toxoplasma gon-
dii, an obligate intracellular protozoan parasite that
infects a wide range of hosts, including humans [1]. As
an opportunistic human pathogen, T. gondii causes a
devastating disease in immunocompromised individuals
and congenitally infected neonates or children [2]. Dur-
ing pregnancy, the infection can result in the vertical
transmission of T. gondii tachyzoites and the parasitic
infestation can negatively affect the developing fetus [1].
The parasite reaches the fetus via the placenta, causing
varying degrees of damage [3]. The frequency of con-
genital transmission increases according to the stage of
the pregnancy, although the severity of the fetal infection
decreases with this gestational progression [4, 5]. Most
infected newborns have no symptoms at birth, but
serious clinical manifestations can develop during child-
hood and early adulthood [6].
T. gondii was originally found as a clonal population
derived in three lineages (I, II and III), predominantly
observed in North America and Europe [7]. Genotypes
not fitting within the three dominant lineages were clas-
sified as “atypical”, with a distinct genotype pattern hav-
ing been demonstrated in Central and South America,
where an abundance of different strain types has been
found [8–11]. In Brazil, there are four clonal lineages, des-
ignated as BrI, BrII, BrIII, and BrIV [8, 12], and two para-
site strains were obtained from chickens in Uberlândia
city, Minas Gerais [13]. They were named the TgChBrUD1
strain, which exhibited the ToxoDB PCR-RFLP geno-
type #11 (also known as type BrII), and the TgChBrUD2
strain, which exhibited the ToxoDB PCR-RFLP geno-
type #6 (also known as type BrI and Africa 1).
The severity of the congenital disease is related to the
gestational age at maternal infection, the concentration of
parasites, the maternal/fetal immune response and the T.
gondii type strain [14]. Recent research supports the
concept that many atypical genotypes differ in pathogen-
icity and transmissibility from typical genotypes [14–16].
Because of the differential virulence of various T. gondii
genotypes, the vertical transmission through the placenta
and the immune responses might depend on strain varia-
tions [17]. Our previous studies have shown that these
Brazilian strains (TgChBrUD1 and TgChBrUD2) are viru-
lent in cells and animal models [13, 18, 19]. In addition,
we demonstrated that re-infection with TgChBrUD1 or
TgChBrUD2 atypical strains in rodents previously infected
by the ME49 clonal strain promoted the vertical trans-
mission of T. gondii, breaching the protection against
congenital toxoplasmosis [19]. It means that atypical
strains can present different behaviors in comparison to
clonal strains, which shows the need for studies that
clarify the immune mechanisms and treatment strategies
against these strains.
In pregnant women with a confirmed diagnosis of toxo-
plasmosis through serology, PCR, utero ultrasound, or
maternal clinical symptoms, anti-parasitic treatment is
indicated [1]. Spiramycin is a macrolide antibiotic used to
decrease the frequency of vertical transmission. However,
if fetal infection occurs, a combination of pyrimethamine,
sulfadiazine and folinic acid is used for the treatment of
congenital toxoplasmosis [20, 21]. Pyrimethamine is a
drug that prevents the growth and reproduction of T. gon-
dii in cells. In the first trimester of gestation, this drug is
not used, because of its potentially teratogenic properties
toward the fetus. Thus, the folinic acid is used to prevent
the hematological toxicities of pyrimethamine [1, 22, 23].
Azithromycin, another macrolide antibiotic, is a derivative
of erythromycin with an anti-Toxoplasma effect [24–27]. It
is widely used for the treatment of community-acquired
pneumonia, Chlamydia during pregnancy, and has activity
against Plasmodium spp. [28, 29]. Our previous studies
have shown that azithromycin was able to control the verti-
cal transmission of T. gondii in Calomys callosus rodents
and in human BeWo trophoblast cells, demonstrating the
important protective effect of azithromycin against this
parasite in the maternal-fetal interface [24, 25]. In addition,
in human villous explants from the third trimester of preg-
nancy infected with T. gondii, the treatment with azithro-
mycin was able to control the replication of RH strain
tachyzoites [27]. Another important effect of macrolide
antibiotics is to exert anti-inflammatory activity and im-
munomodulatory effects [30–32]. Our previous study
showed that azithromycin treatment induces an anti-
inflammatory response in human BeWo trophoblastic
cells infected by T. gondii [25].
Considering that T.gondii virulent strains are predomin-
ant in Brazil and the effectiveness of traditional therapy
may not be the same, the present study aimed to evaluate
the infection rate of these Brazilian strains in human vil-
lous explants from third trimester pregnancies, as well as
the efficacy of azithromycin in the control of these strains
compared to traditional therapy (spiramycin or the com-
bination of sulfadiazine plus pyrimethamine).
Methods
Placenta samples and human villous explants culture
Third-trimester human placentas (36 to 40 weeks of preg-
nancy, n = 6) were collected after elective cesarean section
deliveries at the Clinics Hospital of the Federal University
of Uberlândia (HC-UFU), MG, Brazil. Exclusion criteria
included pre-eclampsia, chronic hypertension, infectious
disease including toxoplasmosis, chorioamnionitis, chronic
renal disease, cardiac disease, connective tissue disease,
pre-existing diabetes mellitus and gestational diabetes
mellitus. Placental tissues were washed in ice-cold sterile
PBS (pH 7.2) to remove excess blood, and then aseptically
dissected using a stereomicroscope to remove endometrial
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tissue and fetal membranes up to 1 h after collection. Ter-
minal chorionic villi containing five to seven free tips per
explant were collected as described previously [27, 33, 34].
Explants were added to 96-well plates (one per well) and
cultured in RPMI 1640 medium (Cultilab, Campinas,
SP, Brazil) supplemented with 10% fetal bovine serum
(FBS) (Cultilab), 100 U/mL penicillin, and 100 μg/mL
streptomycin (Sigma-Aldrich Co., St. Louis, MO,
USA) – complete medium at 37 °C and 5% CO2. The
institutional ethics committee approved the study
(Approval Number: 1.155.475).
Parasite strains
Tachyzoites of RH, ME49, TgChBrUD1 or TgChBrUD2
strains were maintained in human trophoblast cells
(BeWo line) cultured in RPMI medium containing 2%
FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.
The cell culture-derived parasites were stained with 0.4%
Trypan blue and counted in a hemocytometric chamber
to determine the concentrations of viable parasites to be
used in experimental infection protocols.
Antibiotics
Azithromycin (Biofarma, Uberlândia, MG, Brazil), spira-
mycin (Sigma) and a drug combination (PS) consisting
of pyrimethamine (Sigma) and sulfadiazine (Sigma) were
dissolved in DMSO (stock solution) to a concentration
of 10,000 μg/mL for azithromycin, spiramycin, sulfadia-
zine and 3000 μg/mL for pyrimethamine. Stock solutions
were freshly reconstituted and different drug concentra-
tions were used for the treatment of villous explants.
Tissue viability
In the first step of experiments, it was verified whether the
drugs selected for treatment protocols could be toxic for
placental explants. Tissue viability was analyzed by LDH
assay and the tissue integrity by morphological analyses.
LDH assay
In order to verify the toxicity of antibiotics in human vil-
lous explants, placental explants were evaluated for via-
bility using an LDH assay [27].
The villous explants were collected and cultured in
complete medium at 37 °C and 5% CO2. After 24 h, villi
were treated with azithromycin (1000 μg/mL), spiramy-
cin (1000 μg/mL) or a combination of sulfadazine plus
pyrimethamine (200 μg/mL + 150 μg/mL, respectively).
Drug concentrations were based on a previous study by
our research group which showed parasite control with
these doses [27]. In this study we treated the villous ex-
plants with different concentrations of azithromycin
(200, 1000 or 5000 μg/mL) or PS (200, 1000 or 5000 μg/mL
for pyrimethamine; 150, 750 or 3750 μg/mL for sulfa-
diazine). The concentrations of 200 or 1000 μg/mL did
not cause significant cytotoxicity in villous explants and
significantly reduced intracellular proliferation of T. gondii
at both tested concentrations. Therefore, we choose the
1000 μg/mL concentration for experiments. As a control,
villous explants were treated only with complete medium,
corresponding to 100% viability. After 24 h of treatment,
the supernatants were collected for the measurement of
lactate dehydrogenase (LDH), according to the manufac-
turer’s instructions (LDH Liquiform, Labtest Diagnostica
S.A., Lagoa Santa, MG, Brazil). Briefly, the supernatants
collected were incubated with working reagent (NADH
360 μmol/L; sodium azide 0.095%; buffer 250mmol/L;
sodium pyruvate 6mmol/L) for 1min at 37 °C. Then,
absorbance was measured in a DU-70 spectrophotometer
(Beckman, Brea, CA., USA) at 340 nm, for 2min. The
enzyme LDH catalyzes the conversion of pyruvate to lac-
tate in the presence of NADH. In addition, the decrease in
absorbance at 340 nm due to the oxidation of NADH is
proportional to the activity of LDH in the sample. Data
were expressed as U/L of enzyme activity. Two placentas
were used, and consequently, two independent experi-
ments were performed in five replicates.
Morphological analysis
In parallel, we evaluated the integrity of human villous
explants after treatment with different antibiotics. For
this purpose, villi were fixed in 10% buffered formalin,
dehydrated in increasing alcohol concentrations, and
finally embedded in paraffin. Then, 4 μm sections were
made using a microtome and placed on glass slides. In the
next step, villous sections were stained with hematoxylin
and eosin, and morphological analyses were performed
using a light microscope (BX40 Olympus, Tokyo, Japan)
[27]. We evaluated morphological aspects of the syncytio-
trophoblast and cytotrophoblast cells, as well as the mes-
enchyme. Two placentas were used and two independent
experiments were performed in five replicates.
Villous explants infection and treatments
Villous explants were collected and cultured in complete
medium for 24 h. After, villi were infected with T. gondii
tachyzoites (1 × 106 parasites per well) of RH, ME49,
TgChBrUD1 or TgChBrUD2 strains. After 24 h, the villous
explants were washed with complete medium to remove
non-adhered parasites and treated for an additional 24 h
with azithromycin (AZ) (1000 μg/mL), spiramycin (ESP)
(1000 μg/mL) or a combination of 200 μg/mL pyrimeth-
amine plus 150 μg/mL sulfadiazine (PS) in complete
medium. Infected/untreated villous explants were cultured
with complete medium only and included as an experi-
mental control. Afterwards, culture supernatants were col-
lected and stored at − 80 °C for further cytokine detection.
Villous explants were collected for morphological analysis
or T. gondii intracellular proliferation assay by quantitative
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real-time PCR (qPCR). Four placentas were used, and
consequently, four independent experiments were per-
formed, at least, in duplicate.
Quantitative real-time PCR
Total DNA was extracted from villous explants using
the Wizard® Genomic DNA Purification Kit (Promega
Co., Madison, WI, USA), according to the manufacturer’s
instructions. Total DNA was quantified by UV spec-
trophotometry (ND1000 Spectrophotometer; NanoDrop
Technologies, Wilmington, Delaware, USA). Real-time
PCR was performed with a StepOnePlus® Real-Time PCR
System (Applied Biosystems, Carlsbad, CA, USA) and
QuantiNova SYBR Green PCR Kit (Qiagen), according to
the manufacturer’s instructions. The reaction conditions
followed the procedure described [35]. The primers (for-
ward, 5′- TCCTCACCCTCGCCTTCAT-3′ and reverse,
5′-GCTCCTCCAGCCGTCTTG-3′) were engineered to
detect the repetitive area of 529 bp in T. gondii. Positive
and negative parasite controls were included in each assay.
The reaction was carried out with 200 ng of DNA targets
and a 100 ng DNA standard curve was concomitantly
performed on each reaction in a seven time dilution
series. The threshold cycle (Ct) value for each sample
was compared to the standard control and the para-
site quantity was analyzed. The data were presented
in T. gondii DNA (100 ng/μl).
Furthermore, the mean ± SEM were used to express
index of parasites replication, and the inhibition of growth
parasites (%) in the presence of the drugs were calculated
as follows: the average of parasite intracellular prolifera-
tion analyzed in untreated villous explants corresponded
to 100%, then inhibition percentages (%) under drug treat-
ments were calculated by subtracting the percentage
values obtained in treated villous explants with each anti-
biotic from those obtained with untreated villous explants.
Cytokines detection
The concentrations of cytokines were measured by sand-
wich ELISA. The IL-6, TNF-α, TGF-β1 (OpTEIA, BD
Bioscience, San Diego, CA, USA) and MIF (Duoset R&D
Systems, Minneapolis, MN, USA) cytokines were mea-
sured according to the manufacturer’s instructions. The
concentrations of cytokines in culture supernatants were
calculated from a standard curve of each human recombin-
ant cytokine. The limit of detection was according to the
last point of the standard curve (IL-6: 4.7 pg/mL; TNF-α:
7.8 pg/mL; TGF-β1: 125.0 pg/mL and MIF 7.8 pg/mL). The
data regarding cytokines were normalized by the ratio
between the concentration of cytokines in pg/mL and the
concentration of total proteins from the Bradford assay
in μg/mL, resulting in pg/μg of tissue.
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA).
All data were expressed as mean ± standard error of the
mean (SEM). The comparison between infected groups
(Control) with infected and treated groups (AZ or ESP
or PS) was analyzed by Student’s t test. The comparison
of the data from treated or untreated strain groups
were analyzed by the One-way ANOVA test and the
Newman-Keuls post-test. Nonparametric data were
analyzed by the Kruskal-Wallis test and Dunn’s Mul-
tiple Comparison post-test. Statistical significance was
established when P < 0. 05.
Results
Villous explants maintain tissue viability after treatments
Villous explant viability after treatment with azithromy-
cin (AZ), spiramycin (ESP) or pyrimethamine and sulfa-
diazine (PS) was evaluated using the LDH assay and
morphological analysis (Fig. 1). No significant difference
in LDH secretions was observed between uninfected/
treated villous explants and uninfected/untreated vil-
lous explants (Fig. 1a). Also, treatment with either drug
did not induce morphological alterations in villous
explants (Fig. 1b-e). Syncytiotrophoblasts covering the
chorionic villous were observed, but there were no
morphological changes in the cytotrophoblasts and
mesenchymal tissue (Fig. 1b-e).
Villous explants infected with TgChBrUD1 strain present
higher parasite burden and azithromycin reduces the
tissue parasitism in all strain types
The parasite intracellular proliferation in villous explants
was determined using quantitative real-time PCR (Fig. 2).
In the absence of treatment, TgChBrUD1-infected villous
explants showed higher parasite burden when compared
to RH-, ME49- or TgChBrUD2-infected villous explants
(P < 0.05) (Fig. 2a). Treatment with either AZ or ESP or
PS significantly reduced the intracellular proliferation of
T. gondii, regardless T. gondii strain, in comparison to
untreated villous explants (P < 0.05) (Fig. 2b-d). The
villous explants infected with the TgChBrUD1 strain
presented higher parasite burden compared to explants
infected with the ME49 or TgChBrUD2 strain after AZ
treatment (P < 0.05) (Fig. 2b). When treated with ESP, the
villous explants infected with the ME49 or TgChBrUD1
strains presented higher parasite burden compared to
explants infected with the RH or TgChBrUD2 strains
(P < 0.05) (Fig. 2c). The treatment with PS was able to
control all strains equally (P < 0.05) (Fig. 2d). The effect of
drugs in parasite replication for each strain was also evalu-
ated by T. gondii growth inhibition, as shown in Table 1.
The treatments resulted in a significant inhibition of
tachyzoite growth for all T. gondii strains. In addition, no
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significant difference was observed between drugs in
infected villous explants, regardless of the strain (Table 1).
MIF, IL-6 and TGF-β1 production is higher in TgChBrUD1-
infected villous explants
After evaluating the tissue parasitism in villous explants
infected with different strains, we measured the cytokine
levels (Fig. 3). Villous explants infected by RH, ME49 or
TgChBrUD2 strains did not change the MIF, IL-6, TNF
or TGF-β1 production in relation to uninfected villous
(Fig. 3a-d). On the other hand, villous explants infected
by TgChBrUD1 significantly increased MIF and TGF-β1
release in comparison to untreated villous (P < 0.05,
Fig. 3a, d). In addition, TgChBrUD1 induced increased
MIF, IL-6 and TGF-β1secretion in relation to villous
explants infected by RH (P < 0.05, Fig. 3a, b and d). ME49
infection caused higher MIF production only when com-
pared to RH-infected villi (P < 0.05, Fig. 3a). Furthermore,
TgChBrUD1 triggered high MIF and TGF-β1 levels when
compared to ME49-infected villi (P < 0.05, Fig. 3a, d).
Villous explants infected with TgChBrUD2 induced lower
MIF, IL-6 and TGF-β1 levels in comparison to TgChBrUD1
and, at the same time, triggered lower MIF production in
relation to the ME49 strain (P < 0.05, Fig. 3a, b and d).
a
b
d
c
e
Fig. 1 (a) Tissue viability in human villous explants. Villous explants supernatants were collected and lactate dehydrogenase (LDH) activity was
measured using the LDH Liquiform kit. Villous explants were treated with azithromycin (1000 μg/mL) (AZ), spiramycin (1000 μg/mL) (ESP) or
pyrimethamine (200 μg/mL) and sulfadiazine (150 μg/mL) (PS) for 24 h and the tissue toxicity was analyzed. Two placentas were used and two
independent experiments were performed in five replicates. (ANOVA, P < 0.05). Representative photomicrographs of untreated human villous
explants (b), or treated with azithromycin (c), spiramycin (d) or pyrimethamine and sulfadiazine (e). Arrows indicate syncytiotrophoblast layers and
M indicates mesenchymal tissue. Haematoxylin and eosin stain. Bar scale: 200 μm
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Finally, no change in TNF production was observed for any
experimental conditions (Fig. 3c).
TgChBrUD1 and/or TgChBrUD2 strains modulate MIF
production in treated villous explants
After verifying the cytokine profile in untreated villous
explants infected with different T. gondii strains, we
verified the cytokine release in infected villous explants
treated with the panel of selected drugs (Fig. 4).
Villous explants treated with AZ and infected by either
RH or TgChBrUD2 strains up-regulated MIF production
in comparison to infected/untreated villi (P < 0.05, Fig. 4a).
No significant differences were found between villous
explants infected with ME49 or TgChBrUD1 strains and
infected/untreated villi (Fig. 4a). Also, there were no signifi-
cant differences in MIF production between infected vil-
lous explants, independent of the strain, after treatment
with AZ (Fig. 4a).
Villous explants treated with ESP and infected by RH
or TgChBrUD2 up-regulated the MIF production in
comparison to infected/untreated villi (P < 0.05, Fig. 4b).
No significant differences were found between villous
explants infected with the ME49 or TgChBrUD1 strains
and infected/untreated villi (Fig. 4b). ESP-treated villous
explants infected with TgChBrUD1 or TgChBrUD2 in-
creased the MIF release in relation to villi infected with
ME49 or RH and treated with ESP (P < 0.05, Fig. 4b).
The PS treatment increased MIF production by villous
explants infected with RH, ME49 or TgChBrUD2 in rela-
tion to untreated/infected villi (P < 0.05, Fig. 4c); however,
there was no significant difference in MIF production by
villous explants infected with TgChBrUD1 in relation to
untreated/infected villi (Fig. 4c). There were no significant
differences between infected villous explants, independent
of the strain, after treatment with PS (Fig. 4c).
IL-6 and TGF-β1 production were down-regulated by
treatments in villous explants infected with ME49 or
TgChBrUD1
Also, the production of IL-6 and TGF-β1 was analyzed
between infected villous explants (untreated group) and
infected/treated villous explants (treated group) for each
drug (Figs. 5 and 6).
The AZ and ESP treatments decreased the IL-6 pro-
duction by villous explants infected with the ME49 or
TgChBrUD1 strains in comparison to untreated/in-
fected villi (P < 0.05, Fig. 5a-b). No significant differences
were found between villous explants infected with RH or
TgChBrUD2 strains and infected/untreated villi (Fig. 5a-b).
The comparison between infected villous explants treated
with AZ showed that TgChBrUD1 infected villous explants
produced less IL-6 than RH, ME49 (P < 0.05) (Fig. 5a).
In addition, villous treated with AZ and infected by
TgChBrUD2 upregulated IL-6 release if compared to
a
b
c
d
Fig. 2 Parasite burden in infected human villous explants. The
villous explants were infected with RH, ME49 or TgChBrUD1 (UD1)
or TgChBrUD2 (UD2) (a) and treated with (b) azithromycin
(1000 μg/mL) (AZ), (c) spiramycin (1000 μg/mL) (ESP) or (d)
pyrimethamine (200 μg/mL) and sulfadiazine (150 μg/mL) (PS). The
explants were collected and parasites were quantified at real-time
PCR. The threshold cycle (Ct) value for each sample was compared
to the standard control and the parasite quantity was analyzed.
The data were presented in T. gondii DNA (100 ng/μl). Four
placentas were used and four independent experiments were
performed at least in duplicate. *Comparison between untreated/
infected villous explants and infected/treated villous explants
(Student’s t test, mean ± standard error of the mean (SEM),
P < 0.05); #Comparison in relation to RH-infected villous explants;
$Comparison in relation to ME49-infected villous explants;
&Comparison in relation to UD1-infected villous explants;
(ANOVA and Newman-Keuls multiple comparison test,
mean ± standard error of the mean (SEM), P < 0.05)
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Table 1 Tachyzoite growth inhibition in infected villous explants after treatments
Strain/Drug Parasite replication indexa Inhibition of growth parasites (%)b
RH/without treatment 927.9 ± 344.7 –
RH/AZ 241.1 ± 90.69* 74
RH/ESP 181.4 ± 168.7* 80
RH/PS 40,33 ± 25.58* 96
ME49/without treatment 705.4 ± 285.4 –
ME49/AZ 166.0 ± 164.7* 76
ME49/ESP 136,2 ± 110.7* 81
ME49/PS 35.75 ± 16.50* 95
UD1/without treatment 2095.0 ± 608.9 –
UD1/AZ 197.0 ± 232.1* 91
UD1/ESP 135.9 ± 135.6* 94
UD1/PS 21.45 ± 13.18* 99
UD2/without treatment 404.7 ± 226.4 –
UD2/AZ 42.50 ± 24.92* 89
UD2/ESP 26.53 ± 10.89* 93
UD2/PS 29.14 ± 16.13* 93
Tachyzoite growth inhibition in villous explants infected with RH, ME49, TgChBrUD1(UD1) or TgChBrUD2 (UD2) strains and treated with azithromycin (AZ),
spiramycin (ESP) or pyrimethamine and sulfadiazine (150 μg/mL) (PS). aIndex of parasites replication was expressed in mean ± SD from three independent
experiments in three replicates. bInhibition of growth parasites percentage in relation to untreated villous explants. *Statistically significant differences in relation
to the absence of treatment (control) P < 0.05
a b
c d
Fig. 3 Cytokine production by human villous explants infected or not with RH, ME49, TgChBrUD1 (UD1) or TgChBrUD2 (UD2) strain. Supernatants
were collected after 24 h of infection and the production of (a) MIF, (b) IL-6, (c) TNF and (d) TGF-β1 was measured by sandwich ELISA. Four
placentas were used and four independent experiments were performed at least in duplicate. *Comparison in relation to uninfected villous
explants. #Comparison in relation to RH-infected villous explants. $Comparison in relation to ME49-infected villous explants. &Comparison in
relation to UD1-infected villous explants. MIF/IL-6/TGF-β (ANOVA and Newman-Keuls multiple comparison test, mean ± standard error of the
mean (SEM), P < 0.05. TNF (Kruskal-Wallis and Dunn’s multiple comparison test, median with range, P < 0.05)
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TgChBrUD1-infected and treated explants (P < 0.05)
(Fig. 5a). When the infected villous explants were treated
with spiramycin, lower IL-6 production by TgChBrUD1
infected villous explants was observed compared to
RH-infected villous explants (P < 0.05) (Fig. 5b).
The PS treatment decreased IL-6 production by
villous explants infected with the TgChBrUD1 strain
(P < 0.05), but no significant differences were found in
IL-6 production by villous explants infected with the
RH, ME49 or TgChBrUD2 strains compared with in-
fected villous explants (Fig. 5c). The TgChBrUD1 and
TgChBrUD2 infected villous explants treated with PS
produced less IL-6 than ME49-infected and treated vil-
lous explants (P < 0.05) (Fig. 5c).
When the TGF-β1 cytokine was analyzed, it was ob-
served that treatment with AZ or ESP reduced TGF-β1
production by villous explants infected with the RH or
TgChBrUD1 strain compared to infected and untreated
villous explants (P < 0.05) (Fig. 6a and b).
In the AZ-treated group, no significant differences
were observed in TGF-β production by infected villous
a
b
c
Fig. 4 MIF production by human villous explants infected with RH,
ME49, TgChBrUD1 (UD1) or TgChBrUD2 (UD2) strains and treated
with (a) azithromycin (1000 μg/mL) (AZ), (b) spiramycin (ESP)
(1000 μg/mL) or (c) pyrimethamine (200 μg/mL) and sulfadiazine
(150 μg/mL) (PS). As a control, villous explants were only infected
with RH, ME49, UD1 or UD2 (Control). Supernatants were collected
after 24 h of infection and the production of MIF was measured by
sandwich ELISA. Four placentas were used and four independent
experiments were performed at least in duplicate. *Comparison
between infected villous explants and infected treated villous
explants (Student’s t test, mean ± standard error of the mean (SEM),
P < 0.05; #Comparison in relation to RH-infected/treated villous
explants; $Comparison in relation to ME49-infected/treated villous
explants; &Comparison in relation to UD1-infected/treated villous
explants (ANOVA and Newman-Keuls multiple comparison test,
mean ± standard error of the mean (SEM), P < 0.05)
a
b
c
Fig. 5 IL-6 production by human villous explants infected with RH,
ME49 or TgChBrUD1 (UD1) or TgChBrUD2 (UD2) strain and treated
with (a) azithromycin (1000 μg/mL) (AZ), (b) spiramycin (ESP)
(1000 μg/mL) or (c) pyrimethamine (200 μg/mL) and sulfadiazine
(150 μg/mL) (PS). As a control, villous explants were only infected
with RH, ME49, UD1 or UD2 (Untreated). Supernatants were
collected after 24 h of infection and the production of MIF was
measured by sandwich ELISA. Four placentas were used and four
independent experiments were performed at least in duplicate.
*Comparison between infected villous explants and infected treated
villous explants (Student’s t test, mean ± standard error of the mean
(SEM), P < 0.05; $Comparison in relation to ME49-infected/treated
villous explants; &Comparison in relation to UD1-infected/treated
villous explants (ANOVA and Newman-Keuls multiple comparison
test, mean ± standard error of the mean (SEM), P < 0.05)
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explants, regardless of the strain (Fig. 6a). In the
ESP-treated group, the ME49 and TgChBrUD2-infected
villous explants produced higher levels of TGF-β1 than
RH-infected villous explants (P < 0.05) (Fig. 6b). Further-
more, during ESP treatment, TgChBrUD1-infected villous
explants produced lower TGF-β1 levels compared to
ME49-infected villous explants, while TgChBrUD2-infected
villous explants produced higher TGF-β1 levels compared
with TgChBrUD1-infected villous explants (P < 0.05)
(Fig. 6b). The treatment with PS increased TGF-β1 pro-
duction in the TgChBrUD2-infected villous explants
compared to the untreated group or the ME49-, RH-
or TgChBrUD1-infected and treated villous explants
(P < 0.05) (Fig. 6c).
Discussion
Molecular studies of isolated strains of T. gondii from
South America have shown a high frequency of atypical
genotypes, suggesting a high level of diversity in T. gon-
dii [36]. Researchers have suggested that many atypical
genotypes differ in pathogenicity and transmissibility
from typical genotypes [15, 16, 19, 37], since congenital
toxoplasmosis is more prevalent in South America com-
pared to Europe, and more often associated with severe
symptoms, usually as a result of infection with atypical
strains [38, 39]. Therefore, the effectiveness of treatment in
North America and Europe may not be the same, as more
virulent strains of atypical genotypes may predominate [40].
In the present study, a different infection rate was
demonstrated for the Brazilian strain in third trimester
human villous explants. TgChBrUD1-infected villous
explants presented a higher parasite burden than RH-,
ME49- or TgChBrUD2-infected villous explants and
produced high MIF, IL-6 and TGF-β1 levels. Cells and
animal models have already been used to determine the
virulence of the Brazilian strain. In BeWo cells, it was
observed that TgChBrUD2 infection induced lower in-
fection index/replication compared to TgChBrUD1 [41].
In C. callosus rodents, it was observed that both males
and females were highly susceptible to infection by the
TgChBrUD1 or TgChBrUD2 strain, with mortality after
9 days of infection by the parasite [18]. In a previous
study using the same animal model, it was shown that
when groups of re-infected animals were compared,
TgChBrUD2 re-infected females were more susceptible
during pregnancy. This group presented lower survival,
higher morbidity scores, an increased number of pregnant
animals with fetal reabsorption and a high fetal loss rate
[19]. Curiously, although the TgChBrUD1 and TgChBrUD2
strains belong to an atypical strain, they presented different
parasite burdens. In addition, the cytokine production was
also different in this study. TgCHBrUD1-infected villous
explants produced high levels of MIF, IL-6 and TGF-β1,
but TgCHBrUD2-infected villous explants produced low
levels of these cytokines. This result suggests that, although
the polymorphisms in the alleles of DNA fragments pro-
posed by Su et al. [42] elucidate aspects of molecular
epidemiology and population genetics, they underestimate
the biological diversity between strains. In different experi-
mental models, Brazilian strains had different behaviors.
Congenital toxoplasmosis can be reduced to a different
degree when prenatal treatment is started in early preg-
nancy [43, 44]. The rapid initiation of therapy to the in-
fected pregnant women is still important, because fetal
infection follows shortly after maternal infection [43]. If
a
c
b
Fig. 6 TGF-β production by human villous explants infected with
RH, ME49 or TgChBrUD1 (UD1) or TgChBrUD2 (UD2) strain and
treated with (a) azithromycin (1000 μg/mL) (AZ), (b) spiramycin (ESP)
(1000 μg/mL) or (c) pyrimethamine (200 μg/mL) and sulfadiazine
(150 μg/mL) (PS). As a control, villous explants were only infected
with RH, ME49, UD1 or UD2 (Untreated). Supernatants were
collected after 24 h of infection and the production of MIF was
measured by sandwich ELISA. Four placentas were used and four
independent experiments were performed at least in duplicate.
*Comparison between infected villous explants and infected treated
villous explants (Student’s t test, mean ± standard error of the mean
(SEM), P < 0.05; $Comparison in relation to ME49-infected/treated
villous explants; &Comparison in relation to UD1-infected/treated
villous explants (ANOVA and Newman-Keuls multiple comparison
test, mean ± standard error of the mean (SEM), P < 0.05)
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fetal infection is confirmed by amniocentesis, or if the
mother is infected in late pregnancy and there is a high
risk of intrauterine infection, pyrimehtamine and sulfadia-
zine with folic acid should be used to reduce the risk of
congenital toxoplasmosis [22, 45]. Thus, in the present
study, the efficacy of AZ in the control of Brazilian strains
compared to traditional therapy was investigated.
First, the drug concentrations used (1000 μg/mL for
both AZ and ESP, and a combination of 200 μg/mL for
pyrimethamine plus 150 μg/mL for sulfadiazine) were se-
lected based on a previous study that showed the lowest
toxicity in the placental villous for these doses [27]. As
expected, villous explants maintained viability after treat-
ments, with no morphological alterations observed.
In the present study, villous explants treated with
either AZ, ESP or PS reduced the intracellular prolifera-
tion of T. gondii, independent of the strain, compared
with untreated villous explants. Furthermore, AZ treat-
ment inhibited the parasite in the same way as classical
treatments, regardless of the strain. Previous studies by
our research group demonstrated that AZ treatment
controlled the tachyzoites replication in BeWo cells and
villous explants from the third trimester of pregnancy
infected with the RH strain [25, 27]. Macrolide antibi-
otics such as azithromycin bind to the 50S ribosomal
subunit and prevent protein biosynthesis on the plas-
tid ribosome, showing a characteristic “delayed death
phenotype”, presumably due to their ability to induce
a time-dependent reduction in the copy number of
the apicoplast genome anti-parasitic activity [46, 47].
Thus, it was demonstrated that AZ controlled tachy-
zoites replication of the Brazilian strain in the same
way as conventional drugs, showing an alternative drug
for the prevention of toxoplasmosis by atypical strains. T.
gondii elicits different innate immune responses and viru-
lent strains fail to establish a life-long chronic infection,
killing the host prematurely due to hyperinflammation or
heavy parasite burden depending on the host [48–50]. In
addition, because of the apparently different virulence of
various T. gondii genotypes, studies showed altered im-
mune responses against particular genotypes [51–54].
Thereby, this parasite seemingly has the ability to deter-
mine its own destiny by maximizing its persistence and
minimizing host immunopathology [55]. In the present
study, it was observed that villous explants infected with
the TgChBrUD1 strain presented higher parasite burden
than explants infected with other strains after AZ treat-
ment. In the ESP treatment, the villous explants infected
with ME49 or TgChBrUD1 presented a higher parasite
burden compared to explants infected with the RH or
TgChBrUD2 strains. The cytokine analysis showed high
MIF levels produced by RH- or TgChBrUD2-infected
villous explants, and no difference in the IL-6 level com-
pared to the control after AZ or ESP treatment. On the
other hand, no difference was observed in MIF production
by villous explants infected with the ME49 or TgChBrUD1
strains and low IL-6 levels compared to the control after
AZ or ESP treatment. MIF is a soluble pro-inflammatory
cytokine released by activated immune-competent cells
that may act as an activator of innate immunity, regulating
subsequent adaptive immune responses and modulat-
ing some cells responses [56–58]. In a previous study,
our group demonstrated that MIF production by the
human first-trimester placenta is up-regulated by
parasite antigens (STAg) and may play an essential
role as an autocrine/paracrine mediator in placental
infection by T. gondii [59]. Moreover, studies observed
high MIF production in (BeWo) human trophoblast cells
and human villous explants from first- and third-trimester
pregnancies, demonstrating a potential control in the
immune response to T. gondii infection at maternal-fetal
interface [34, 60]. IL-6 is fundamental in the process of
embryo implantation and a variety of cell populations are
known to produce IL-6 in the placental microenvironment
[61, 62]. This cytokine participates in the protective im-
mune response against infectious agents and IL-6 has
been demonstrated to be necessary for anti–T. gondii
immunity [63], but an imbalance of IL-6 signaling through
the gp130 receptor subunit could make IL-6 a patho-
logical rather than a protective factor [64]. In the present
study, the action of AZ or ESP associated with mecha-
nisms of MIF can be hypothesized to explain the low para-
site burden observed in villous explants infected with the
RH or TgChBrUD2 strains. On the other hand, the low
IL-6 level and the unchanged MIF production by villous
explants infected with TgChBrUD1 after treatments can
be associated with higher parasitism than other strains,
but the action of drugs is able to control T. gondii infec-
tion. TGF-β1 seems to be important for dampening the
inflammatory response and minimizing the damage
caused by inflammation in TgChBrUD1-infected villous
explants, but no relationship with treatments was ob-
served in the present study. It is important to emphasize
that macrolide antibiotics have anti-inflammatory activity
and immunomodulatory effects [32] that may have influ-
enced cytokine production by villous explants.
Interestingly, the TgChBrUD2 (genotype 6 type BrI
Africa 1) strain presented nine type I alleles out of 12
genetic markers and killed infected animals within a
short period of time. In contrast, the TgCHBrUD1
(genotype 11 type BrII) strain showed five markers with
the type I allele, two type II alleles and five markers of
type III alleles [13]. In the present study, the analysis of
parasitism and cytokine production by villous explants
infected by clonal or Brazilian strains showed similar re-
sults to the RH and TgChBrUD2 strains. The same
phenomenon was observed for ME49 and TgChBrUD1. It
has been suggested that distinct combinations of alleles in
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several loci may be responsible for the heterogeneity ob-
served in the virulence phenotype of T. gondii strains [65].
Studies by our research group demonstrated the rela-
tionship between apoptosis modulation during T. gondii
infection and the virulence characteristics of the para-
site. It was observed that the incidence of apoptosis in
BeWo cells was differentially modulated by highly (RH)
or moderately virulent (ME49) strains of T. gondii, since
RH-infected BeWo cells had a lower incidence of apop-
tosis compared to the ME49 strain [66]. Therefore,
ME49-infected BeWo cells exhibited a predominantly
pro-inflammatory response profile, with the higher se-
cretion of MIF, TNF-α, IL-12, IL- 17A and IL-6,
whereas RH-infected cells showed a higher production
of anti-inflammatory cytokines such as TGF-β and
IL-10 [67]. Thus, the highly (RH and TgChBrUD2) or
moderately (ME49 and TgChBrUD1) virulent strains
can modulate, differently, important defense mechanisms
in hosts to sustained intracellular survival. In the present
study, it is possible to associate the cytokine production
and parasite burden with the virulence of strains, as viru-
lent strains induced less MIF and TGF-β production than
strains with moderate virulence. Therefore, the treatments
also influenced the cytokine production and parasitism,
since differences in cytokine production were observed
after treatments and there was a lower parasite burden
than in untreated villous explants.
Conclusion
In conclusion, the azithromycin treatment was as effect-
ive as the conventional treatment of human placental
villi infected with T. gondii, regardless of the strain, sug-
gesting that it may be an alternative drug for the preven-
tion of congenital infection. In addition, the TgChBrUD1
strain was able to replicate more in villous explants than
other strains and modulate important cytokines involved
in parasite control, showing that different strains have
different strategies to evade the host immune response
and ensure survival.
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